3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 4
1
Phase 1/2
1
Status
Recruiting
3
Terminated
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
32
Carcinoma, Non-Small-Cell Lung
29
Leukemia, Myeloid, Acute
27
Melanoma
25
Neoplasms
22
Lymphoma
21
Pancreatic Neoplasms
18
Multiple Myeloma
18
Recurrence
17
Lung Neoplasms
17
Leukemia
17
Ovarian Neoplasms
16
Neoplasm Metastasis
15
Lymphoma, Non-Hodgkin
15
Carcinoma, Hepatocellular
15
Colorectal Neoplasms
14
Lymphoma, Follicular
13
Myelodysplastic Syndromes
12
Lymphoma, B-Cell
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Prostatic Neoplasms
10
Lymphoma, Mantle-Cell
10
Brain Neoplasms
10
Stomach Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
9
Liver Neoplasms
9
Glioma
9
Interventions
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Withdrawn
×
Acquired Immunodeficiency Syndrome
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn